GRAINGER DAVID J 4
4 · Centessa Pharmaceuticals plc · Filed Feb 1, 2022
Insider Transaction Report
Form 4
GRAINGER DAVID J
Chief Innovation Officer
Transactions
- Purchase
Ordinary Shares
2022-01-28$9.05/sh+27,500$248,754→ 27,500 total(indirect: See footnote)
Holdings
- 813,756
Ordinary Shares
Footnotes (2)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Held by RxCelerate Limited ("RxCelerate"). The Reporting Person is a member of the board of directors of RxCelerate. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by RxCelerate, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.